medigen.com.tw
Molecular Diagnostics | Medigen Biotech Corp.
http://www.medigen.com.tw/en/molecular-diagnostics
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group. Medigen’s strategy for developing Nuclear Acid Testing (NAT) products is via global merger and acquisition (M&A). In 2004, Medigen acquired Texas BioGene Inc.(TBG). Furthermore, strategic alliance was formed with Perkin Elmer in Nov. 2012 through the sale of Shanghai Haoyuan Biotech equity stakes for $38.0 million in cash. To take advantage of Taiwan’s strength in electronics, TBG developed one of the first SMART Automation System fo...
medigen.com.tw
Our Vision | Medigen Biotech Corp.
http://www.medigen.com.tw/en/our-vision
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group.
medigen.com.tw
OBP-301 | Medigen Biotech Corp.
http://www.medigen.com.tw/en/obp-301
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group. OBP-301 is a genetic treatment using adenovirus target specifically to cancer cells only. When entering into cancer cells, virus particles disrupt the infected cancer cells from proliferating.
medigen.com.tw
News | Medigen Biotech Corp.
http://www.medigen.com.tw/en/category/news
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group. Archive by Category "News". A Great Showdown of Medigen BioMedical Group in BioTaiwan 2016. TBG Diagnostics Limited listed on Australian Securities Exchange (ASX) on February 3, 2016. Winston was interviewed by local television channel. MVC was granted National Innovation Award for the application of cell-based production technologies in mock-up vaccine manufacturing. Medigen published the discovery of human native mAb at PEGS 2015.
medigen.com.tw
Company Overview | Medigen Biotech Corp.
http://www.medigen.com.tw/en/company-overview
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group. MBC) was established in late 1999. The company upholds the vision of Innovations for a better life focusing on the development of new therapies for liver diseases and cancers. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering new drug development, innovative drug discovery, molecular diagnostics, vaccine, and generic drugs.
medigen.com.tw
Drug Development | Medigen Biotech Corp.
http://www.medigen.com.tw/en/drug-development
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group.
medigen.com.tw
Careers | Medigen Biotech Corp.
http://www.medigen.com.tw/en/careers
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group. Medigen aims to become a leading biotech company in Asia. People sharing the same vision and ambition are welcome to join Medigen. We are looking for people with passion, integrity, knowledge, and responsibility. Find your fit at:.
medigen.com.tw
Management | Medigen Biotech Corp.
http://www.medigen.com.tw/en/management
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group.
medigen.com.tw
PI-88 (MUPARFOSTAT) | Medigen Biotech Corp.
http://www.medigen.com.tw/en/muparfostat-pi-88
Medigen Vaccine Biologics Corporation. Winston Medical & Biotech Group. Bayer’s Nexavar was approved by USFDA and EMA in 2007 for treatment of advanced-stage liver cancer. But its usage for treating early stage (about 30%) and intermediate stage (about 45%) liver cancer has not been approved by USFDA. Hence, there is unmet need for adjuvant therapy in preventing liver cancer recurrence after liver resection. PI-88 (MUPARFOSTAT) PHASE II TRIAL (CT-PI-21) ADJUVANT THERAPY FOR HCC AFTER CURATIVE SURGERY.